Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients

Table 4 Frequency of severity scores for immunosuppressive adverse effects ^a

Adverse effects	0	1+	2+	3+	Overall frequency (as %)
Vomiting	30 / 27	0 / 1	0 / 0	NA	0 / 3.57
Diarrhea	28 / 20	2 / 8	0 / 0	NA	6.67 / 28.6
Dyspepsia	19 / 14	9 / 5	2 / 9	0 / 0	36.7 / 50.0
Acid suppressive therapy	12 / 9	18 / 16	0 / 3	NA	60.0 / 67.9
Acne ^b	26 / 21	4 / 4	0 / 3	0 / 0	13.3 / 25.0
Skin changes	21 / 21	8 / 5	1 / 2	0 / 0	30.0 / 25.0
Hirsutism	22 / 22	7 / 3	1 / 3	0 / 0	26.7 / 21.4
Moon facies	13 / 17	15 / 11	2 / 0	0 / 0	56.7 / 39.3
Gingival hyperplasia	7 / 22	21 / 6	2 / 0	NA	76.7 / 21.4
Buffalo hump^c	21 / 22	9 / 6	NA	NA	30.0 / 21.4
Tremor	13 / 7	15 / 16	2 / 4	0 / 1	56.7 / 75.0
Headache^c	28 / 22	2 / 6	NA	NA	6.67 / 21.4
Insomnia	22 / 15	5 / 9	2 / 4	1 / 0	26.7 / 46.4
Myopathy	27 / 24	2 / 4	1 / 0	0 / 0	10.0 / 14.3
Ophthalmic changes^c	17 / 18	13 / 10	NA	NA	43.3 / 35.7
Mania	29 / 28	1 / 0	0 / 0	NA	3.33 / 0
Depression	26 / 18	4 / 4	0 / 6	0 / 0	13.3 / 35.7
Post-transplant diabetes mellitus^c	21 / 19	9 / 9	NA	NA	30.0 / 32.1

Data displayed as cyclosporine and MMF regimen (n = 30) / tacrolimus and EC-MPS regimen (n = 28).
^aSeverity score determined using Tables 1 and 2; ^bNo patients received a 4+ for acne; ^c rated as present or absent.
NA, non-applicable since no rating; MMF, mycophenolate mofetil; EC-MPS, enteric coated mycophenolate sodium.

ISSN: 1471-2369